First Oral Option for Dermatomyositis Gets FDA Green Light

(MedPage Today) -- The FDA approved the first oral treatment option for the autoimmune disorder dermatomyositis. Brepocitinib (Lisraya) is indicated for adults with the rare condition, which causes chronic inflammation, progressive muscle weakness...